115 related articles for article (PubMed ID: 22472987)
1. Interpatient pharmacokinetic and pharmacodynamic variability of carrier-mediated anticancer agents.
Caron WP; Song G; Kumar P; Rawal S; Zamboni WC
Clin Pharmacol Ther; 2012 May; 91(5):802-12. PubMed ID: 22472987
[TBL] [Abstract][Full Text] [Related]
2. The effects of nanoparticle drug loading on the pharmacokinetics of anticancer agents.
Petschauer JS; Madden AJ; Kirschbrown WP; Song G; Zamboni WC
Nanomedicine (Lond); 2015 Feb; 10(3):447-63. PubMed ID: 25707978
[TBL] [Abstract][Full Text] [Related]
3. Formulation and physiologic factors affecting the pharmacology of carrier-mediated anticancer agents.
Lucas AT; Madden AJ; Zamboni WC
Expert Opin Drug Metab Toxicol; 2015; 11(9):1419-33. PubMed ID: 26173794
[TBL] [Abstract][Full Text] [Related]
4. Clinical pharmacokinetics and pharmacodynamics of anticancer agents in pediatric patients (review).
Knoester PD; Underberg WJ; Beijnen JH
Anticancer Res; 1993; 13(5C):1795-808. PubMed ID: 8267385
[TBL] [Abstract][Full Text] [Related]
5. Concept and clinical evaluation of carrier-mediated anticancer agents.
Zamboni WC
Oncologist; 2008 Mar; 13(3):248-60. PubMed ID: 18378535
[TBL] [Abstract][Full Text] [Related]
6. Methods and Study Designs for Characterizing the Pharmacokinetics and Pharmacodynamics of Carrier-Mediated Agents.
Schorzman AN; Lucas AT; Kagel JR; Zamboni WC
Methods Mol Biol; 2018; 1831():201-228. PubMed ID: 30051434
[TBL] [Abstract][Full Text] [Related]
7. Challenges in preclinical to clinical translation for anticancer carrier-mediated agents.
Lucas AT; Madden AJ; Zamboni WC
Wiley Interdiscip Rev Nanomed Nanobiotechnol; 2016 Sep; 8(5):642-53. PubMed ID: 26846457
[TBL] [Abstract][Full Text] [Related]
8. Population pharmacokinetic/pharmacodynamic modeling for the time course of tumor shrinkage by motesanib in thyroid cancer patients.
Lu JF; Claret L; Sutjandra L; Kuchimanchi M; Melara R; Bruno R; Sun YN
Cancer Chemother Pharmacol; 2010 Nov; 66(6):1151-8. PubMed ID: 20872145
[TBL] [Abstract][Full Text] [Related]
9. Complex effects of tumor microenvironment on the tumor disposition of carrier-mediated agents.
Lucas AT; Price LS; Schorzman A; Zamboni WC
Nanomedicine (Lond); 2017 Aug; 12(16):2021-2042. PubMed ID: 28745129
[TBL] [Abstract][Full Text] [Related]
10. Factors affecting the pharmacokinetics and pharmacodynamics of liposomal drugs.
Song G; Wu H; Yoshino K; Zamboni WC
J Liposome Res; 2012 Sep; 22(3):177-92. PubMed ID: 22332871
[TBL] [Abstract][Full Text] [Related]
11. Delivery of anticancer drugs.
Zee-Cheng RK; Cheng CC
Methods Find Exp Clin Pharmacol; 1989; 11(7-8):439-529. PubMed ID: 2689812
[TBL] [Abstract][Full Text] [Related]
12. Clinical pharmacology of anticancer agents in relation to formulations and administration routes.
Terwogt JM; Schellens JH; Huinink WW; Beijnen JH
Cancer Treat Rev; 1999 Apr; 25(2):83-101. PubMed ID: 10395834
[TBL] [Abstract][Full Text] [Related]
13. Clinical pharmacokinetics and pharmacodynamics of anticancer drugs in children.
Rodman JH; Relling MV; Stewart CF; Synold TW; McLeod H; Kearns C; Stute N; Crom WR; Evans WE
Semin Oncol; 1993 Feb; 20(1):18-29. PubMed ID: 8475406
[TBL] [Abstract][Full Text] [Related]
14. Pharmacokinetic study of pegylated liposomal CKD-602 (S-CKD602) in patients with advanced malignancies.
Zamboni WC; Strychor S; Maruca L; Ramalingam S; Zamboni BA; Wu H; Friedland DM; Edwards RP; Stoller RG; Belani CP; Ramanathan RK
Clin Pharmacol Ther; 2009 Nov; 86(5):519-26. PubMed ID: 19675541
[TBL] [Abstract][Full Text] [Related]
15. [Clinical pharmacology in development of new anticancer agents].
Sasaki Y
Gan To Kagaku Ryoho; 1994 Oct; 21 Suppl 3():310-4. PubMed ID: 7986109
[TBL] [Abstract][Full Text] [Related]
16. Microdialysis for pharmacokinetic-pharmacodynamic studies.
Yu W; Cheng Q; Feng J; Li F
Pharmazie; 2007 Dec; 62(12):883-91. PubMed ID: 18214337
[TBL] [Abstract][Full Text] [Related]
17. Antitumor efficacy of cisplatin-loaded glycol chitosan nanoparticles in tumor-bearing mice.
Kim JH; Kim YS; Park K; Lee S; Nam HY; Min KH; Jo HG; Park JH; Choi K; Jeong SY; Park RW; Kim IS; Kim K; Kwon IC
J Control Release; 2008 Apr; 127(1):41-9. PubMed ID: 18234388
[TBL] [Abstract][Full Text] [Related]
18. Novel marine-derived anticancer agents: a phase I clinical, pharmacological, and pharmacodynamic study of dolastatin 10 (NSC 376128) in patients with advanced solid tumors.
Madden T; Tran HT; Beck D; Huie R; Newman RA; Pusztai L; Wright JJ; Abbruzzese JL
Clin Cancer Res; 2000 Apr; 6(4):1293-301. PubMed ID: 10778954
[TBL] [Abstract][Full Text] [Related]
19. Factors affecting the pharmacokinetics of pegylated liposomal doxorubicin in patients.
La-Beck NM; Zamboni BA; Gabizon A; Schmeeda H; Amantea M; Gehrig PA; Zamboni WC
Cancer Chemother Pharmacol; 2012 Jan; 69(1):43-50. PubMed ID: 21590446
[TBL] [Abstract][Full Text] [Related]
20. Recent advances in physiologically based pharmacokinetic and pharmacodynamic models for anticancer nanomedicines.
Byun JH; Han DG; Cho HJ; Yoon IS; Jung IH
Arch Pharm Res; 2020 Jan; 43(1):80-99. PubMed ID: 31975317
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
